Worth reading
19Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Who is moving to which position
Resolved 30 March 2026Incoming appointee
8 itemsScheduled Appointment Date1 April 2026
Arai Nobutaka (荒井 信貴)
Previous positionRepresentative Director and Executive Vice President, responsible for the BML Testing Division, General Manager of the Advanced Technology Development Division, and Director of the BML General Research Institute
New positionRepresentative Director and Executive Vice President, responsible for the BML Testing Division, General Manager of the Genomic Medicine Business Division, General Manager of the Genomic QA Office, and Director of the BML General Research Institute
Shibata Kenji (柴田 健治)
Previous positionDirector and Senior Executive Officer, General Manager of the BML Testing Division, General Manager of the General Research Institute's Third Testing Department, General Manager of the General Research Institute's Fourth Testing Department, and General Manager of the Reagent Department
New positionDirector and Senior Executive Officer, General Manager of the BML Testing Division, General Manager of the General Research Institute's Third Testing Department, and General Manager of the Reagent Department
Yamashita Kazuhiro (山下 和宏)
Previous positionExecutive Officer and General Manager of the Electronic Medical Records System Department
New positionExecutive Officer, responsible for the Electronic Medical Records System Department
Kakimoto Atsushi (柿本 篤志)
Previous positionChief Expert, Advanced Medical Development Department
New positionGeneral Manager of the Advanced Genomics Business Division
Yamazaki Toshifumi (山嵜 肇史)
Previous positionDeputy General Manager, General Research Institute's Third Testing Department
New positionGeneral Manager of the Genomic Analysis Business Division
Yokote Tsutomu (横手 勉)
Previous positionGeneral Manager of the Systems Promotion Department
New positionDeputy General Manager of the Systems Division and General Manager of the Systems Promotion Department
Yoshizawa Minoru (吉沢 実)
Previous positionDeputy General Manager and General Manager of the Medical Information Systems Sales Department
New positionDeputy General Manager of the Systems Division and General Manager of the Medical Information Systems Sales Department
Yuasa Miwa (湯浅 美和)
Previous positionDeputy General Manager of the Electronic Medical Records System Department
New positionGeneral Manager of the Electronic Medical Records System Department
| Item | Details |
|---|---|
| Resolution date | 30 March 2026 |
| Scheduled Appointment Date | 1 April 2026 |
| Name of appointee | Arai Nobutaka (荒井 信貴), Shibata Kenji (柴田 健治), Yamashita Kazuhiro (山下 和宏), Kakimoto Atsushi (柿本 篤志), Yamazaki Toshifumi (山嵜 肇史), Yokote Tsutomu (横手 勉), Yoshizawa Minoru (吉沢 実), Yuasa Miwa (湯浅 美和) |
| Appointee's new position | Representative Director and Executive Vice President, responsible for the BML Testing Division, General Manager of the Genomic Medicine Business Division, General Manager of the Genomic QA Office, and Director of the BML General Research Institute, Director and Senior Executive Officer, General Manager of the BML Testing Division, General Manager of the General Research Institute's Third Testing Department, and General Manager of the Reagent Department, Executive Officer, responsible for the Electronic Medical Records System Department, General Manager of the Advanced Genomics Business Division, General Manager of the Genomic Analysis Business Division, Deputy General Manager of the Systems Division and General Manager of the Systems Promotion Department, Deputy General Manager of the Systems Division and General Manager of the Medical Information Systems Sales Department, General Manager of the Electronic Medical Records System Department |
| Appointee's previous position | Representative Director and Executive Vice President, responsible for the BML Testing Division, General Manager of the Advanced Technology Development Division, and Director of the BML General Research Institute, Director and Senior Executive Officer, General Manager of the BML Testing Division, General Manager of the General Research Institute's Third Testing Department, General Manager of the General Research Institute's Fourth Testing Department, and General Manager of the Reagent Department, Executive Officer and General Manager of the Electronic Medical Records System Department, Chief Expert, Advanced Medical Development Department, Deputy General Manager, General Research Institute's Third Testing Department, General Manager of the Systems Promotion Department, Deputy General Manager and General Manager of the Medical Information Systems Sales Department, Deputy General Manager of the Electronic Medical Records System Department |
Items this document does not state (16)
Date of departureAppointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeName of departing officerFormer position of departing officerNew position of departing officerReason for departureWhether the incumbent will remain in officeReason for changeReasons for appointmentNumber of directors after the changeFiling as an independent officerDetails of organizational changesChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.No reason for the personnel change was provided.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.